News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer
The ICR has expressed disappointment at the decision by NICE not to recommend abiraterone as a first-line treatment on the NHS for newly diagnosed, advanced prostate cancer.
Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma
A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma – a common childhood tumour with a low survival rate.
Breast cancer drug capivasertib enters major trial
A major phase III trial of capivasertib, a cancer drug discovered following collaborative work between The Institute of Cancer Research, London, and partners, has begun in breast cancer.
-content.tmb-hbmobile.jpg?Culture=en&sfvrsn=fec93f9d_2 "Dispensing medicines for a clinical trial (Jan Chlebik for the ICR, 2014) content")
New class of precision medicine strips cancer of its DNA defences
A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class.
AACR Virtual Annual Meeting 2020: Personalised cancer vaccine shows promise in early trial
A personalised cancer vaccine, used in combination with an immunotherapy drug, triggers a response from the immune system that is specific to the cancer and shows some clinical benefit, according to the results of an early clinical trial presented at the virtual AACR conference.
Cancer’s reliance on fat could be targeted with new ‘drugs and diet’ treatment
Cancers are often heavily reliant on breaking down fats for their growth and spread, and could be treated by a highly innovative combination of new drugs and dietary changes, a major new study concludes.
ICR ramps up lab research after lockdown
ICR researchers are returning to their labs this week as we start to ramp up our pioneering cancer research following the disruption caused by the pandemic.
ICR and Cancer Research UK spinout company Monte Rosa Therapeutics launches with library of anti-cancer compounds
A company formed as a spinout from Cancer Research UK-funded science at The Institute of Cancer Research, London, has been publicly launched – revealing $32.5m in funding and a library of innovative anti-cancer compounds.
Isabella’s gift: The precious donation aiding vital research into childhood brain cancer
The parents of Isabella Ortiz, who died from a brain tumour, have highlighted the need for rare tissue donation, to help other children facing the same condition.
ICR statement regarding Black Lives Matter
As an organisation that believes passionately in equality, we want to express our solidarity with our Black, Asian and minority ethnic staff following the death of George Floyd.
Mini tumours help predict how cancer handles the heat of innovative cancer treatments
Scientists have shown that therapies which combine heat and radiation have a different effect on lab-grown mini tumours than they do on lab-grown cancer cells grown in a more traditional way in a two-dimensional layer.
Pioneer in building collaboration across research fields joins as Scientific Director of the Cancer Research UK Convergence Science Centre
The Institute of Cancer Research, London, and Imperial College London have appointed a leading expert in building interdisciplinary partnerships to head our joint Cancer Research UK Convergence Science Centre.
